Cue Biopharma, Inc. filings document material events, governance actions, operating results, and capital-structure matters for a clinical-stage biopharmaceutical company focused on immune-modulating biologics. The company's 8-K reports cover executive transitions, collaboration milestones, financial results, registered common stock matters, and amendments related to a reverse stock split.
Proxy and meeting-related filings describe director elections, auditor ratification, executive compensation votes, stockholder proposal procedures, and amendments to governing documents. Other disclosures address research and development programs including CUE-401, CUE-501, the Immuno-STAT platform, collaboration and license agreements, equity compensation arrangements, and risk factors associated with clinical-stage biotechnology operations.
Cue Biopharma appointed Lucinda WarrenChief Financial and Business Officer
Warren has over 30 years of global experience in pharmaceuticals and biotechnology, including a decade in business development roles at Johnson & Johnson and leadership positions at Janssen organizations. She receives no additional compensation for these new responsibilities, her employment terms remain unchanged, and there are no related-party or family relationships tied to her appointment.
Cue Biopharma director Peter A. Kiener reported a new stock option grant dated 01/02/2026. He received a stock option for 24,400 shares of Cue Biopharma common stock with an exercise price of $0.34 per share, recorded as an acquisition of derivative securities. The option was granted under the company’s Director Compensation Policy and is scheduled to become fully exercisable on the first anniversary of the grant date, with an expiration date of 01/01/2036. Following this grant, Kiener beneficially owns 24,400 stock options directly.
Cue Biopharma, Inc. reported a routine insider transaction showing a stock option grant to director Pamela Garzone. On 01/02/2026, she received 24,400 stock options with an exercise price of $0.34 per share. According to the disclosure, the award was granted under the company’s Director Compensation Policy.
The filing states that this stock option becomes fully exercisable on the first anniversary of the grant date and carries an expiration date of 01/01/2036. Following this grant, Garzone beneficially owns 24,400 derivative securities directly, reflecting only this option award.
Cue Biopharma director Sarraf Pasha reported receiving a stock option award from the company. On 01/02/2026, Pasha was granted an option to buy 24,400 shares of Cue Biopharma common stock at an exercise price of $0.34 per share, with no cash paid for the grant itself. The award was made under the company’s Director Compensation Policy.
The filing states that this option becomes fully exercisable on the first anniversary of the grant date and carries an expiration date of 01/01/2036. Following this grant, Pasha beneficially owns 24,400 derivative securities in the form of these stock options, held directly.
Cue Biopharma is conducting a public offering of common stock, pre‑funded warrants and common stock warrants, all sold together as units. The pre‑funded warrants have a de minimis exercise price and are exercisable on a cashless basis, while the common stock warrants are exercisable for five years and may be cashless if no effective registration is available.
The company is a clinical‑stage biopharmaceutical developer using its Immuno‑STAT platform to target disease‑specific T cells in autoimmune diseases. As of September 30, 2025, it held $18.7 million in cash, cash equivalents and marketable securities and has a collaboration providing a $5.0 million upfront payment and a further $5.0 million time‑based payment due in December 2025, which together are expected to fund operations into the third quarter of 2026. Management states there is substantial doubt about the company’s ability to continue as a going concern and that proceeds from this offering will not be sufficient to remove that doubt, and notes that additional equity financing is likely to be dilutive.
Cue Biopharma, Inc. (CUE) reported a Form 4 transaction for its Chief Business Officer. The officer received a stock option grant covering 125,000 shares of Cue Biopharma common stock on 09/29/2025. The option has an exercise price of $0.72 per share and expires on 09/28/2035.
According to the filing, this stock option becomes fully exercisable on the first anniversary of the grant date, meaning the officer must wait one year before the option is fully vested. Following this grant, the officer beneficially owns 125,000 derivative securities, held directly. This transaction reflects equity-based compensation designed to align the officer’s interests with those of shareholders.
Cue Biopharma, Inc. (CUE) reported an equity award to its chief development officer. The reporting person received a stock option covering 50,000 shares of common stock at an exercise price of $0.72 per share on 09/29/2025. This option is scheduled to become fully exercisable on the first anniversary of the grant date and carries an expiration date of 09/28/2035. After this grant, the reporting person holds 50,000 derivative securities related to Cue Biopharma common stock with direct ownership.
Cue Biopharma, Inc. reported that on November 24, 2025 it made an updated corporate presentation publicly available on its website and furnished that presentation as Exhibit 99.1 to a Form 8-K. The company notes that the materials provided under Item 7.01, including the presentation, are being furnished rather than filed under the Exchange Act, which means they are not subject to certain liabilities associated with filed reports and are not automatically incorporated into other securities filings unless specifically referenced.
Cue Biopharma, Inc. (CUE) announced that Chief Medical Officer Matteo Levisetti will leave the company, with his employment ending on November 28, 2025. The company and Dr. Levisetti agreed to his separation on November 17, 2025.
Subject to signing and not revoking a separation and release of claims agreement, Dr. Levisetti will receive a lump-sum cash severance of $556,837.60, equal to nine months of base salary plus a prorated portion of his 2025 target bonus, paid in the first regular payroll cycle after the separation agreement becomes effective. If he elects COBRA coverage, Cue Biopharma will pay the full premiums for up to nine months after the Separation Date, or until he secures reasonably comparable new coverage or COBRA otherwise ends.
Cue Biopharma reported third‑quarter results, highlighting lower collaboration revenue and continued operating losses, alongside a new collaboration that adds near‑term cash. Collaboration revenue was $2.1 million versus $3.3 million a year ago. Operating expenses totaled $9.7 million, yielding a net loss of $7.4 million (vs. $8.7 million in Q3 2024).
Liquidity remained tight with cash, cash equivalents and marketable securities of $18.7 million as of September 30, 2025, and management disclosed “substantial doubt” about continuing as a going concern. A subsequent Collaboration and License Agreement with ImmunoScape includes upfront payments totaling $15.0 million; approximately $10.0 million is due in Q4 2025 (of which $5.0 million has been received), and $5.0 million before the first anniversary of the effective date. Term loans are due on December 1, 2025. As of November 7, 2025, shares outstanding were 78,737,736.